Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 9/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.35 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652009 | 0.80 | KMT2A (0.35) | KDM4EALDH1A1TYMS | |
| SCHEMBL25815335 | 0.78 | KCNA5 (0.36) | KDM4E | |
| SCHEMBL25388131 | 0.76 | HPGD (0.35) | KDM4EALDH1A1HPGDTYMS | |
| SCHEMBL19253836 | 0.74 | TYMS (0.34) | KDM4EALDH1A1TYMS | |
| SCHEMBL25390339 | 0.74 | MAPT (0.33) | KDM4EALDH1A1HPGD | |
| SCHEMBL20012256 | 0.72 | ALDH1A1 (0.47) | CHUKLRRK2ALDH1A1HPGDTYMS | |
| SCHEMBL17652035 | 0.71 | LMNA (0.35) | KDM4EALDH1A1TYMS | |
| SCHEMBL17652032 | 0.71 | TYMS (0.34) | KDM4EALDH1A1TYMS | |
| SCHEMBL25389586 | 0.71 | MEN1 (0.38) | TYMS | |
| SCHEMBL19253834 | 0.71 | MPO (0.39) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188553-B1 | COMPOUNDS | PROVOST FELLOWS FOUND SCHOLARS & OTHER MEMBERS BOARD COLLEGE HOLY & UND (IE) | 2024-05-08 | — | — | EP | disclosed |
| US-20230295165-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-21 | — | — | US | disclosed |
| CN-116783197-A | Compounds of formula (I) | 都柏林圣三一学院教务长、研究员、基金会学者及董事会其他成员 | 2023-09-19 | — | — | CN | disclosed |
| US-20230286987-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-14 | — | — | US | disclosed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| EP-4188553-A1 | COMPOUNDS | The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, (IE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4188932-A1 | COMPOUNDS | The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, (IE) | 2023-06-07 | — | — | EP | disclosed |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | THE PROVOST, THE FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-12-06 | — | — | US | disclosed |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | THE PROVOST, THE FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-12-06 | — | — | US | disclosed |
| WO-2022023438-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-02-03 | — | — | WO | disclosed |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-09-14 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| EP-3201198-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3200798-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016050806-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050804-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050804-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050806-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | TYMS, DPYD, C5 | CHUK 216/4885LRRK2 3305/4885MCL1 1637/4885 |
| US-20230295165-A1 | COMPOUNDS | NR3C1, NR3C2, CBR3 | CHUK 1812/4885LRRK2 2441/4885MCL1 2846/4885 |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | TYMS, C5, HRH3 | CHUK 234/4885LRRK2 2876/4885MCL1 1331/4885 |
| US-20230286987-A1 | COMPOUNDS | HAX1, NHERF1, CXCR1 | CHUK 1560/4885LRRK2 3023/4885MCL1 878/4885 |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | QTRT1, QTRT2, HPRT1 | CHUK 1809/4885LRRK2 4271/4885MCL1 4451/4885 |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | NDUFAB1, FH, TFAM | CHUK 1819/4885LRRK2 1388/4885MCL1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.